Gemini Therapeutics, Inc. (GMTX) Research

Gemini Therapeutics, Inc. operates as a clinical-stage precision medicine enterprise, dedicated to crafting various therapeutic solutions for age-related macular degeneration (AMD) with a genetic foundation. Its flagship investigational product, GEM103, is a recombinant human complement factor H protein engineered to address dry AMD in patients. Beyond this, the firm is progressing GEM307, aimed at treating systemic ailments. Established in 2015, Gemini Therapeutics' operations are based out of Cambridge, Massachusetts.

Market snapshot

Symbol
GMTX
Price
$1.35
Day change
0.00%
Market cap
$25.5M
52-week range
1.35-24.7
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Allakos Inc. (ALLK)
  • Angion Biomedica Corp. (ANGN)
  • AnPac Bio-Medical Science Co., Ltd. (ANPC)
  • Elevation Oncology, Inc. (ELEV)
  • Freeline Therapeutics Holdings plc (FRLN)
  • Liminal BioSciences Inc. (LMNL)
  • LakeShore Biopharma Co., Ltd (LSB)
  • Serina Therapeutics, Inc. (SER)

Recent insider activity

  • Bitterman Kevin — S-Sale (20000 shares) on 2024-01-10
  • Atlas Venture Fund X, L.P. — S-Sale (30000 shares) on 2024-01-10
  • Atlas Venture Fund X, L.P. — S-Sale (20000 shares) on 2024-01-10
  • Quisel John D — M-Exempt (2700 shares) on 2023-12-29
  • Quisel John D — M-Exempt (2700 shares) on 2023-12-29

Open Gemini Therapeutics, Inc. (GMTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.